Purpose: To evaluate the clinical outcomes of diabetic macular oedema (DMO) patients treated with Avastin (bevacizumab) in a single clinic, and to compare these results with published study data. Patients and methods: This retrospective study included patients treated with Avastin for DMO between January 1, 2019, and December 31, 2022. A total of 64 patients (72 eyes) were analyzed, comprising 30 men and 34 women with a mean baseline age of 65.3 ± 12.1 years. Baseline and follow-up measurements were taken at every visit which included central retinal thickness (CRT) and best-corrected visual acuity (BCVA). Data was evaluated to assess changes in CRT and BCVA after treatment. Results: The mean baseline CRT was 550.06 ± 129.54 µm, which decreased to an average of 438.69 ± 133.36 µm following treatment, reflecting a significant reduction in macular oedema. BCVA improved from an average of 0.33 ± 0.22 to 0.43 ± 0.28, indicating a measurable improvement in visual acuity. The average follow-up period was 13 months. Discussion: Avastin treatment for DMO demonstrated significant improvements in both anatomical and functional outcomes over the examined period. The reduction in CRT and improvement in BCVA signify role of Avastin as an effective therapeutic option for DMO. These findings contribute to the growing body of evidence supporting its use and provide insights into real-world clinical outcomes. Our results align closely with existing literature on the efficacy of Avastin for DMO.